Indivior PLC (LON:INDV) has been given a consensus recommendation of “Buy” by the seven brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is GBX 482.14 ($6.66).
A number of equities analysts have weighed in on the company. Numis Securities reissued a “buy” rating and set a GBX 640 ($8.84) price objective on shares of Indivior in a research note on Thursday, February 15th. Royal Bank of Canada boosted their price objective on Indivior from GBX 500 ($6.91) to GBX 540 ($7.46) and gave the stock an “outperform” rating in a research note on Friday, January 26th. Jefferies Group reissued a “buy” rating and set a GBX 500 ($6.91) price objective on shares of Indivior in a research note on Wednesday, January 17th. Morgan Stanley reissued an “equal weight” rating and set a GBX 410 ($5.66) price objective on shares of Indivior in a research note on Friday, December 1st. Finally, Citigroup raised Indivior to a “buy” rating and boosted their price objective for the stock from GBX 280 ($3.87) to GBX 490 ($6.77) in a research note on Wednesday, November 8th.
Shares of Indivior (INDV) traded up GBX 5 ($0.07) on Tuesday, hitting GBX 380.50 ($5.26). The company had a trading volume of 1,710,107 shares, compared to its average volume of 1,880,000. Indivior has a 52-week low of GBX 246.50 ($3.41) and a 52-week high of GBX 436.60 ($6.03). The stock has a market capitalization of $2,750.00 and a PE ratio of 7,610.00.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.com-unik.info/2018/02/20/indivior-plc-indv-given-consensus-recommendation-of-buy-by-brokerages-2.html.
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.